17-50188131-C-T
Variant summary
Our verdict is Pathogenic. Variant got 17 ACMG points: 17P and 0B. PM2PM5PP2PP3_StrongPP5_Very_Strong
The NM_000088.4(COL1A1):c.3226G>A(p.Gly1076Ser) variant causes a missense change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G1076C) has been classified as Pathogenic.
Frequency
Consequence
NM_000088.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 17 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
COL1A1 | NM_000088.4 | c.3226G>A | p.Gly1076Ser | missense_variant | 44/51 | ENST00000225964.10 | NP_000079.2 | |
COL1A1 | XM_011524341.2 | c.3028G>A | p.Gly1010Ser | missense_variant | 41/48 | XP_011522643.1 | ||
COL1A1 | XM_005257058.5 | c.2956G>A | p.Gly986Ser | missense_variant | 42/49 | XP_005257115.2 | ||
COL1A1 | XM_005257059.5 | c.2308G>A | p.Gly770Ser | missense_variant | 31/38 | XP_005257116.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
COL1A1 | ENST00000225964.10 | c.3226G>A | p.Gly1076Ser | missense_variant | 44/51 | 1 | NM_000088.4 | ENSP00000225964.6 | ||
COL1A1 | ENST00000486572.1 | n.424G>A | non_coding_transcript_exon_variant | 1/2 | 3 | |||||
COL1A1 | ENST00000511732.1 | n.550G>A | non_coding_transcript_exon_variant | 2/2 | 2 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 36
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Pathogenic:3
Likely pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Dec 30, 2019 | The COL1A1 c.3226G>A; p.Gly1076Ser variant (rs67394386) is reported in the literature in multiple individuals who were affected with osteogenesis imperfect, and this variant was de novo in at least two of these individuals (Lindahl 2015, Lund 1997, Malmgren 2017, and Mrosk 2018). This variant is reported in ClinVar (Variation ID: 425618), but is absent from general population databases (Exome Variant Server, Genome Aggregation Database), indicating it is not a common polymorphism. This codon is located in a triple helix repeat domain, and glycine substitutions are the most frequent pathogenic alterations in this region (Ben Amor 2011). The glycine at codon 1076 is highly conserved, and computational analyses (SIFT, PolyPhen-2) predict that this variant is deleterious. Based on available information, this variant is considered to be likely pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jun 14, 2022 | Occurs in the triple helical domain and replaces the glycine in the canonical Gly-X-Y repeat; missense substitution of a canonical glycine residue is expected to disrupt normal protein folding and function, and this is an established mechanism of disease (HGMD); Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 27510842, 29499418, 31994750, 8218237, 32034735, 25944380, 21667357, 29150909, 19344236, 9016532, 17078022, 7695699, 25086671, 27519266, 9101304, 28116328, 29807018, 24863959, 33939306, 24077912, 27535533) - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Nov 21, 2016 | - - |
Osteogenesis imperfecta type III Pathogenic:2
Pathogenic, no assertion criteria provided | clinical testing | Department of Medical Sciences, Uppsala University | - | - - |
Pathogenic, criteria provided, single submitter | research | HudsonAlpha Institute for Biotechnology, HudsonAlpha Institute for Biotechnology | Jan 10, 2019 | ACMG codes: PS2, PS4, PM2, PP3, PP4, PP5 - |
Infantile cortical hyperostosis;C0023931:Osteogenesis imperfecta type I;C0029456:Osteoporosis;C0268358:Osteogenesis imperfecta, perinatal lethal;C0268362:Osteogenesis imperfecta type III;C0268363:Osteogenesis imperfecta with normal sclerae, dominant form;C4551623:Ehlers-Danlos syndrome, arthrochalasia type;C5436842:Combined osteogenesis imperfecta and Ehlers-Danlos syndrome 1 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Juno Genomics, Hangzhou Juno Genomics, Inc | - | PM2_Supporting+PS2_Moderate+PP3_Strong+PP2+PS4 - |
COL1A1-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 20, 2023 | The COL1A1 c.3226G>A variant is predicted to result in the amino acid substitution p.Gly1076Ser. This variant (legacy nomenclature p.Gly898Ser) was reported in multiple individuals with osteogenesis imperfecta, being de novo when parental testing was performed (Lund. 1997. PubMed ID: 9101304; Table S2, Bowling. 2021. PubMed ID: 34930662; Higuchi. 2021. PubMed ID: 33939306; Table S2, Mei. 2022. PubMed ID: 35909573; Han. 2020. PubMed ID: 31994750). This variant is located in the conserved Gly-Xaa-Yaa triple helical domain where substitutions of a glycine are usually pathogenic (Residues 179-1192, https://www.uniprot.org/; Legacy nomenclature in Marini. 2007. PubMed ID: 17078022 indicates amino acids 1-1012; Symoens. 2014. PubMed ID: 25146735). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. This variant is interpreted as pathogenic. - |
Osteogenesis imperfecta with normal sclerae, dominant form Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Dec 24, 2019 | This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868]. - |
Osteogenesis imperfecta type I Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 18, 2024 | This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 1076 of the COL1A1 protein (p.Gly1076Ser). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with osteogenesis imperfecta (PMID: 9101304, 26177859, 29150909, 29499418). In at least one individual the variant was observed to be de novo. This variant is also known as Gly898Ser. ClinVar contains an entry for this variant (Variation ID: 425618). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt COL1A1 protein function with a positive predictive value of 95%. This variant disrupts the triple helix domain of COL1A1. Glycine residues within the Gly-Xaa-Yaa repeats of the triple helix domain are required for the structure and stability of fibrillar collagens (PMID: 7695699, 8218237, 19344236). In COL1A1, variants affecting these glycine residues are significantly enriched in individuals with disease (PMID: 9016532, 17078022) compared to the general population (ExAC). For these reasons, this variant has been classified as Pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at